Astonin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Astonin

Quick Facts

Property Description
Active ingredient Fludrocortisone acetate
Form Tablet (oral administration)
Pharmacological class Corticosteroid (Mineralocorticoid)
Typical Use Hormonal replacement therapy
Origin Synthetic pregnane steroid

What is Astonin, and What is its Classification?

The drug entity known as Astonin contains the active substance Fludrocortisone acetate, a potent, prescription-only medication administered in the pharmaceutical form of an oral tablet. It is officially classified as a corticosteroid, belonging specifically to the highly specialized group of mineralocorticoids. This classification is distinguished by its dominant effect on mineral and electrolyte regulation, setting it apart from other steroids used primarily for their systemic anti-inflammatory purposes.

Is Fludrocortisone a Natural or Synthetic Compound?

Fludrocortisone is a synthetic pregnane steroid, explicitly manufactured rather than being a natural extract, confirming its origin is synthetic. The active substance is structurally a halogenated derivative of cortisol, chemically designed to mimic the physiological effects of the body's primary endogenous mineralocorticoid, aldosterone. This synthetic design allows for specific control over its high mineralocorticoid potency, a factor clinically recognized for its essential role in maintaining hormonal balance.

What is the General Purpose of Astonin?

The fundamental purpose of this medicine is to provide essential replacement therapy when native mineralocorticoid production is severely deficient. The drug's therapeutic role is supported by its physiological action, which centers on regulating crucial sodium and fluid balance in the kidneys. By promoting sodium retention and increasing the excretion of potassium, the drug helps maintain the critical internal fluid homeostasis necessary for sustained systemic physiological function and blood pressure regulation.

Regulatory References

  1. WHO ATC code
  2. MedlinePlus Drug Information

What side effects are possible with Astonin?

Possible Side Effects and Safety Information

The safety profile for Astonin (fludrocortisone acetate) is documented by regulatory agencies based on the drug's inherent mineralocorticoid and glucocorticoid activities. Adverse reactions are formally classified by frequency and system involvement in official prescribing information.

Adverse Reaction Classifications

The most frequently observed effects are direct consequences of the medication's potent sodium and fluid retention action, which includes hypertension (high blood pressure) and hypokalemia (low potassium in the blood), often classified as Very Common or Common in regulatory documents. Other anticipated effects across system-organ classes include edema (swelling), muscle weakness, and weight gain.

System-Organ Class Examples of Documented Effects
Metabolic/Endocrine Fluid retention, Hypokalemia, Cushingoid features, Hyperglycemia
Musculoskeletal Muscle weakness, Osteoporosis, Pathologic fracture
Ophthalmic Glaucoma, Posterior subcapsular cataracts
Gastrointestinal Peptic ulceration, Abdominal bloating, Pancreatitis

Serious Adverse Reactions and Key Constraints

Official labeling documents severe adverse reactions, including the development or exacerbation of congestive heart failure and peptic ulceration with potential for hemorrhage. The medication's immunosuppressive properties mean that it can increase the body's susceptibility to, or mask signs of, severe infections.

Safety notes specify that effects such as cataracts and osteoporosis are commonly associated with prolonged use. Specific considerations apply to certain populations: children are at risk for growth suppression, and infants born to mothers who received substantial doses may require observation for hypoadrenalism.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage of Astonin (Fludrocortisone acetate) is documented in regulatory labeling as an exacerbation of its potent mineralocorticoid activity, requiring immediate medical attention if suspected.

Officially Documented Manifestations

A prolonged overdose may lead to hypertension (high blood pressure), edema (swelling), excessive weight gain, and hypokalemia (low serum potassium). More severe, chronic manifestations include cardiac enlargement (cardiomegaly) and congestive heart failure. Patients may also experience muscular weakness and irregular heartbeats associated with severe potassium loss.

Urgent Medical Attention

The official guidance states that immediate medical help must be sought if any overdose is suspected. Urgent intervention is required if an individual has collapsed, experiences trouble breathing, has a seizure, or cannot be awakened. Regulatory documents warn that adverse effects from overdosage carry a risk of life-threatening reactions, particularly in older adults.

Supportive Management

Management of Astonin overdose is supportive and guided by the official prescribing information. No specific antidote is documented. Treatment involves the discontinuation of the drug for chronic overdosage and comprehensive care including careful monitoring of serum electrolytes and blood pressure. Necessary supportive measures include the administration of potassium supplements and the restriction of dietary sodium intake.

Therapeutic Uses of Astonin

Main Uses of Astonin

Astonin, containing the active ingredient fludrocortisone, is a synthetic corticosteroid primarily used for its potent mineralocorticoid properties. Its main therapeutic application is to compensate for a deficiency in the body's natural production of mineralocorticoid hormones.

Primary Indications

  • Chronic Primary Adrenocortical Insufficiency (Addison's Disease): In this condition, the adrenal glands do not produce enough steroid hormones. Astonin is used as replacement therapy to mimic the action of aldosterone, helping the body manage salt and water balance.
  • Salt-Losing Adrenogenital Syndrome: This is a congenital condition where the adrenal glands produce excess androgens but insufficient mineralocorticoids. Astonin helps prevent excessive sodium loss through the kidneys.

Benefits and Mechanism of Action

The primary benefit of Astonin is its ability to regulate the body's electrolyte balance and fluid volume. It works by acting on the distal tubules of the kidneys to increase the reabsorption of sodium into the bloodstream.

Physiological Effects

  • Sodium Retention: By promoting sodium reabsorption, the medication helps maintain adequate levels of sodium in the blood.
  • Potassium Excretion: As sodium is reabsorbed, the kidneys excrete more potassium, which helps maintain the delicate balance between these two minerals.
  • Blood Pressure Support: Increased sodium levels lead to water retention, which expands the volume of extracellular fluid. This process helps to raise and stabilize blood pressure in patients who would otherwise suffer from chronic hypotension due to mineralocorticoid deficiency.
  • Prevention of Dehydration: By reducing the amount of sodium and water lost in the urine, the medication helps protect patients from severe dehydration and the potentially life-threatening electrolyte imbalances associated with adrenal insufficiency.

Regulatory References

  1. The therapeutic use is verified by authoritative medical information sources, which state its role as partial replacement therapy

Eligibility and Restrictions for Use

The official regulatory profile for Astonin (Fludrocortisone acetate) defines eligibility based on absolute contraindications, infectious status, pre-existing comorbidities, and age.

Populations for Whom Use is Prohibited

Use of this medicine is absolutely contraindicated in patients with Systemic Fungal Infections or known hypersensitivity to fludrocortisone acetate or any excipients [FDA DailyMed]. Furthermore, individuals on immunosuppressive doses must not receive live or live-attenuated vaccines [Health Canada PM].

Eligibility Restrictions and Special Considerations

Category Regulatory Status / Limitation
Infection Status Must not be used for systemic infections unless specific anti-infective therapy is employed [HPRA SmPC].
Organ/Metabolic Caution is required for patients with renal insufficiency, hepatic impairment, diabetes mellitus, and conditions like hypertension or congestive heart failure [FDA DailyMed].
Age Groups Pediatric use carries a risk of growth suppression; Older Adults require careful dosage selection due to potential age-related organ decline [HPRA SmPC].
Reproductive Status Pregnancy use is conditional (Category C), with infants requiring observation for hypoadrenalism. Caution is advised during lactation [FDA DailyMed].

Eligibility is established only for adults and children requiring mineralocorticoid replacement therapy for approved chronic conditions, such as Addison's disease.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Astonin (Fludrocortisone acetate) based on specific metabolic and electrolyte-altering properties.

Interaction Type Interacting Agents Explicitly Documented Regulatory Finding
Metabolic Clearance Rifampin, Phenytoin, Barbiturates These hepatic enzyme inducers increase the metabolic clearance of Fludrocortisone, which may lead to a diminished effect.
Ketoconazole This enzyme inhibitor may decrease corticosteroid clearance, potentially resulting in increased systemic effects.
Electrolyte Balance Potassium-depleting diuretics (e.g., Furosemide), Amphotericin B, Licorice Co-administration enhances the risk of hypokalemia (low potassium), requiring monitoring.
Pharmacodynamic Antagonism Antidiabetic drugs (oral agents and insulin), Antihypertensives Fludrocortisone may diminish the effect of antidiabetics and antagonize the action of antihypertensives.
Gastrointestinal Effects Aspirin/NSAIDs Increased ulcerogenic effect is documented when used concurrently.
Exposure Modification Estrogen (including oral contraceptives) Alters Fludrocortisone exposure by increasing corticosteroid-binding globulin, necessitating careful management upon initiation or termination.

Population-Specific and Contextual Notes:

An enhanced corticosteroid effect is specifically noted in regulatory labels for patients with Hypothyroidism or Cirrhosis. Furthermore, caution is advised regarding Hepatic or Cardiac Disease when combining the steroid with anabolic agents due to the documented enhanced tendency toward fluid retention. There are no mandatory timing separation rules documented in official prescribing information.

Mechanism of Action

How Astonin Works

The mechanism of fludrocortisone centers on its action as an agonist at the intracellular Mineralocorticoid Receptor ( MR), primarily within the epithelial cells of the renal distal tubules. This binding initiates a genomic mechanism where the drug-receptor complex modulates gene transcription in the nucleus, which is the initial step that determines the subsequent mechanistic cascade and causes an inherently delayed onset of effect.

The resulting genomic signal leads to the increased synthesis and activity of cellular transport proteins, specifically the Epithelial Sodium Channel ( ENaC) and the Na^+/ K^+-ATPase pump. This effect enhances the reabsorption of sodium ( Na^+) back into the bloodstream while promoting the excretion of potassium ( K^+), thereby directly manipulating the body’s electrolyte composition. The enhanced reabsorption of sodium is followed by the osmotic reabsorption of water, leading to an expansion of the circulating plasma volume and extracellular fluid volume (ECF). This volume expansion provides a mechanical input to the circulatory system, which is the physiological consequence that ultimately leads to the elevation of systemic blood pressure.

Dosage and Administration Information

How Astonin is Used: Official Administration Guidelines

Astonin, which contains the active ingredient Fludrocortisone acetate, is administered via the oral route as a high-potency hormonal replacement medication. Use follows specific dosing schedules and administration contexts, which must be strictly followed as this is a chronic replacement therapy.


Standard Dosing Regimens

Indication Usual Adult Dose and Frequency
Addison’s Disease 0.1 mg once daily (Range: three times a week up to 0.2 mg daily)
Salt-Losing Adrenogenital Syndrome Range: 0.1 mg to 0.2 mg once daily

For administration, the 0.1 mg tablet is scored to facilitate dose splitting, enabling the required 0.05 mg dose for adjustment purposes. Dosage is subject to continuous monitoring and may be reduced to 0.05 mg daily if transient hypertension is observed.


Procedural Administration Rules

In the context of adrenocortical insufficiency, Fludrocortisone acetate is administered in conjunction with a glucocorticoid for comprehensive hormonal substitution (e.g., hydrocortisone or cortisone). This co-administration is a key principle of the official use protocol. Regarding missed doses, if a scheduled dose is forgotten, it should be taken as soon as possible, but if it is nearly time for the next dose, the forgotten dose must be skipped; a double dose must not be taken to compensate.

Therapy is not to be stopped suddenly; the dosage requires gradual reduction when discontinuation is being considered. Additionally, a supportive dosage of corticosteroids may be required during periods of physiological stress, such as severe illness or surgery, and may be necessary for up to a year following the event.

Recent Clinical Evidence

Recent Clinical Evidence / Overview of Studies

Treatment-Resistant Depression (TRD)

Research has explored whether this combination therapy may be associated with changes in clinical outcomes for individuals with treatment-resistant depression (TRD) who have not responded to initial antidepressant treatment. Studies examined participant reports of depressive symptoms.

  • Phase 3 RCTs: A series of randomized controlled trials (RCTs) involving 450 participants focused on sustained response rates. Studies examining the treatment have often focused on individuals who have not responded to at least two other standard pharmacological interventions.
  • Research Focus: Research explored whether the treatment group demonstrated changes in symptoms.
  • Combination with CBT: Some studies have evaluated the outcomes associated with using this drug in conjunction with cognitive behavioral therapy (CBT).

Chronic Pain Syndromes (CRPS)

Research investigated the outcomes observed in individuals with complex regional pain syndrome (CRPS). Findings were mixed across smaller, open-label studies.

  • Pain Intensity Scales: Research monitored changes in participant-reported pain intensity using the Visual Analog Scale (VAS) over a 12-week period. Evidence remains limited and largely descriptive.
  • Functionality Assessment: Some studies assessed changes in physical functionality metrics, such as range of motion and grip strength.
  • Monotherapy Comparison: Studies have compared outcomes associated with the combination of the two components against monotherapy. The findings from comparison studies were mixed.

Generalized Anxiety Disorder (GAD)

Research has explored the potential of the combination to influence symptoms of Generalized Anxiety Disorder (GAD). Clinical data documented participant-reported changes in anxiety symptoms.

  • Study Population: The majority of studies focused on adults aged 18-65 who met the DSM-5 criteria for GAD.
  • Safety Profile: Research has indicated that this medication may be associated with changes in seizure threshold, and studies often enrolled or excluded individuals based on a history of seizures.
  • Discontinuation Rates: Analysis of trials noted relatively high rates of participant discontinuation.

Key Studies & References

  1. Enduring effects of psychotherapy, antidepressants and their combination for depression: a systematic review and meta-analysis (Supports TRD and combination with CBT findings)
  2. Comparative Remission Rates and Tolerability of Drugs for Generalised Anxiety Disorder: A Systematic Review and Network Meta-analysis (Supports GAD study populations and discontinuation/tolerability context)
  3. Incidence and nature of antidepressant discontinuation symptoms: A systematic review and meta-analysis (Supports GAD discontinuation rates and nature of symptoms like dizziness)

Frequently Asked Questions (FAQ)

Common questions about Astonin (FAQ)

Q: How quickly does Astonin usually start working after the first time taking it?

A: The way Astonin works involves changes at the cellular level, which means its therapeutic effect is not instantaneous. Official information indicates this process causes an inherently delayed onset of effect, which may be noticeable over one to two days after the first dose.

Q: Is Astonin known to interact with common pain relievers like ibuprofen or acetaminophen?

A: Regulatory documents state that Astonin, a corticosteroid, may interact with NSAIDs (such as ibuprofen), which can increase the risk of gastrointestinal ulcers. Specific warnings about the use of acetaminophen (paracetamol) are not routinely highlighted in the core official drug documentation.

Q: What if I have kidney problems—does that prevent me from using Astonin?

A: Official documents advise that caution is required for patients who have renal insufficiency (a type of kidney problem). This is a general safety consideration, and the decision for use is based on a healthcare professional's assessment of the individual's specific health status.

Q: What if I have liver problems—does that prevent me from using Astonin?

A: Official information indicates that caution is required for patients who have hepatic impairment (a type of liver problem). Like other special considerations, the decision for use is based on a healthcare professional's assessment of the individual's specific health status.

Q: Can older people or seniors take Astonin without special concerns?

A: Regulatory documents advise that Older Adults may be more susceptible to the effects of the drug. The use in Older Adults is associated with the need for careful dosage selection due to the potential for age-related changes in organ function.

Q: Is there any information about Astonin use during pregnancy or while breastfeeding?

A: Use during pregnancy is conditional (Category C), and regulatory notes suggest that infants may require observation after birth. Regulatory documents state that caution is advised during lactation (breastfeeding).

Q: Is Astonin considered a long-term treatment or is it usually short-term?

A: The medicine is primarily intended for replacement therapy in chronic conditions, meaning its use is typically long-term. Regulatory guidance describes the use of the lowest effective dose for the minimum time necessary to manage chronic conditions.

Q: If I am allergic to other medications, should I worry about Astonin?

A: The medicine is absolutely contraindicated (use is prohibited) if a person has a known history of hypersensitivity or allergy to fludrocortisone acetate or any of the inactive ingredients it contains. Regulatory guidance focuses on known allergies to the drug itself.

Q: Are there specific symptoms that mean I should contact a healthcare professional immediately while on Astonin?

A: Official safety information documents certain severe adverse reactions that are generally identified as severe or emergent conditions in the official information. These may include the onset of severe swelling of the face, lower legs, or ankles, new or worsening vision problems, muscle weakness, or signs of internal bleeding like black or tarry stools.

Q: Does Astonin interact with birth control pills?

A: Yes, official drug interaction tables mention that Estrogen-containing oral contraceptives may enhance the systemic effects of Astonin by increasing corticosteroid-binding globulin. This interaction may be associated with the need for a dosage adjustment.

Q: What is the definition of the patient population described in the main clinical trials for Astonin?

A: The research overviews included in official documents describe studies involving specific adult populations. These included individuals with treatment-resistant depression (TRD), those with complex regional pain syndrome (CRPS), and adults meeting criteria for Generalized Anxiety Disorder (GAD).

Q: Can Astonin cause changes in mood or make you feel dizzy?

A: Official documents list potential nervous system-related side effects. These include possible changes to mood such as depression and anxiety, as well as physical effects like dizziness and a feeling of restlessness.

Q: Are there any common foods or drinks that should be avoided when taking Astonin?

A: While regulatory documents do not list specific foods to avoid, the drug’s primary function is to retain sodium and fluid. Therefore, the dosage and use conditions require careful monitoring of dietary salt intake to manage the risk of side effects like high blood pressure or fluid retention.

Q: Is it true that Astonin can affect your sleep patterns?

A: Yes, official safety documents list problems with sleep as a potential side effect. Specifically, insomnia (difficulty sleeping) and restlessness are noted in the regulatory information.

Q: Are there different strengths or formulations of Astonin available?

A: The available oral tablets typically contain 0.1 mg of fludrocortisone acetate. Official documents mention that this tablet is scored to facilitate dose splitting, which can enable a 0.05 mg dose for precise adjustment.

Q: Is there any research looking at how Astonin affects children or teenagers?

A: Research overviews often focus on adult populations, but official safety notes describe the use in children as requiring special consideration due to a documented risk of growth suppression.

Q: Why do some people say they feel tired when they first start Astonin?

A: Regulatory safety information lists fatigue and unusual tiredness or weakness as potential side effects. These effects may occur as the body adjusts to the medication.

Q: If I am taking blood pressure medicine, is it safe to take Astonin?

A: Astonin may diminish the effect of antihypertensive (blood pressure) medications. Furthermore, the fluid retention caused by Astonin can independently lead to elevated blood pressure. Official documents note that these interactions may necessitate careful monitoring.

Q: Does taking Astonin increase or decrease your appetite?

A: Official documents list both increased hunger and decreased appetite as potential side effects, indicating the drug may cause changes in a person's desire to eat.

Q: Can Astonin be used by people with a history of heart issues?

A: Official guidance states that caution is a necessary consideration for patients with cardiac disease or a history of congestive heart failure. This is due to the drug’s documented tendency toward causing fluid retention, which can be problematic for the heart.

Q: Is it normal to have a slight headache when you first start taking Astonin?

A: Official regulatory documents list headache as a potential side effect that may be experienced during the initial phase of treatment.

Q: Do official documents mention any difference in how Astonin affects men versus women?

A: Official documents list side effects that are specific to women, such as menstrual irregularities and changes to the menstrual cycle.

Q: Can taking Astonin affect the results of other medical tests?

A: Yes, official documentation notes that the medicine can affect the results of certain medical tests. Regulatory information notes that healthcare professionals may need to be informed of its use prior to certain tests.

Q: Is there a maximum time length that Astonin is typically taken for?

A: The medicine is generally used for chronic replacement therapy. Official documentation does not specify a maximum time length, but regulatory guidance suggests using the lowest effective dose for the minimum period necessary to reduce the risk of potential long-term side effects.

Q: Are there different inactive ingredients in generic Astonin that could cause issues?

A: The core 0.1 mg tablet contains inactive ingredients such as lactose, maize starch, and sodium benzoate. Generic versions may vary in their inactive ingredients. Patients who have concerns about specific components can discuss them with a healthcare professional or pharmacist.

Q: What is the evidence regarding Astonin's use in combination with therapy?

A: Research has evaluated the outcomes associated with using the drug in conjunction with non-drug therapies. Studies focused on certain conditions, such as treatment-resistant depression (TRD), have specifically looked at its use alongside therapies like cognitive behavioral therapy (CBT).

Q: Can Astonin cause skin rashes or sensitivity to the sun?

A: Official documents list several skin-related side effects, including allergic skin rash, hives, and increased sweating. Sun sensitivity (photosensitivity) is not explicitly listed in the core documents.

Q: Are there specific times during treatment when side effects from Astonin are more likely?

A: Patient information indicates that some problems, such as mood changes or stomach problems, may be experienced straight away. Other effects, like weakness or fluid retention, may only become evident after weeks or months of treatment.

How should Astonin be stored and disposed of?

How to Store and Dispose of Astonin

Official regulatory documents define strict temperature and container rules for Astonin (Fludrocortisone acetate) tablets to maintain product stability.

Storage Conditions

The medicine is primarily required to be stored in a refrigerator at a temperature between 2 C and 8 C. The tablets must be protected from freezing and excessive heat, and the container must be kept tightly closed to prevent moisture exposure. The medicine must be stored out of the sight and reach of children.

Temporary storage outside of refrigeration, up to 25 C, may be permitted for a limited time (e.g., 30 days or 3 months, depending on the label). Tablets that have been exposed to this temperature excursion must not be returned to the refrigerator and must be disposed of.

Disposal Instructions

Unused or expired tablets should be disposed of according to local pharmaceutical waste regulations. Regulatory guidance for household disposal includes mixing the tablets with an undesirable substance, placing the mixture in a sealed container, and discarding it in the trash. Personal information should be scratched off the label before disposing of the empty packaging.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Astonin found in:

A-Z Index: